Roche shares dip as oral breast cancer drug fails trial

Roche’s prized breast cancer pill fails closely watched study

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

A setback for Roche's breast cancer drug

Today's biotech news includes Vinay Prasad's brief, chaotic tenure at the FDA, a setback for Roche's breast cancer drug, and more.

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

Roche shares dip as oral breast cancer drug fails trial

Roche shares have dropped after its oral breast cancer drug giredestrant failed to show benefits in a key phase III clinical trial.

Roche breast cancer drug falls short of expectations (for now) - European Biotechnology Magazine

Setback after earlier optimism: the Roche drug giredestrant has delivered mixed clinical data. Several clinical trials had suggested the drug could play an important role in the treatment of hormone-dependent breast tumours and potentially become a blockbuster for the company. Now, however, a key Phase III study has failed to meet its primary endpoint, even as regulatory submissions are already under way. The post Roche breast cancer drug falls …

Roche’s oral SERD fails in Phase III breast cancer trial

In the study, giredestrant showed no statistical improvement in the primary endpoint, but there was a numerical improvement.The post Roche’s oral SERD fails in Phase III breast cancer trial appeared first on Clinical Trials Arena.